AgomAb Therapeutics
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
Operating in biotechnology, health care, therapeutics based in European Union (EU), Europe, Middle East, and Africa (EMEA), AgomAb Therapeutics was founded in 2017.
As a business in biotechnology, health care, therapeutics, AgomAb Therapeutics is listed here with the public details available about it.
The business is associated with European Union (EU), Europe, Middle East, and Africa (EMEA).
It is recorded at the Series_C stage.
Recorded headcount: c_00011_00050 employees.
It has disclosed roughly $237M in funding.
| Sector | Biotechnology, Health Care, Therapeutics |
|---|---|
| Headquarters | European Union (EU), Europe, Middle East, and Africa (EMEA) |
| Founded | 2017 |
| Employees | c_00011_00050 |
| Stage | series_c |
| Total funding | $236,963,512 |
Website: agomab.com
Contact details and direct channels are available to signed-in members.
Create a free account
Create a free account